Triple-negative breast cancer: current understanding and future perspectives

Abstract

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) expression. Consequently, standard hormone and HER2-targeted therapies are ineffective, necessitating reliance on chemotherapy, immunotherapy, antibody-drug conjugates (ADCs), and poly(ADP-ribose) polymerase (PARP) inhibitors forBRCA-mutated cases. TNBC exhibits rapid growth, a high risk of early recurrence, and disproportionately affects younger women, Black women, and BRCA1 mutation carriers. Standard management typically involves neoadjuvant chemotherapy followed by surgery and potential radiation. However, TNBC treatment remains challenging due to its severe biological heterogeneity, high metastatic potential, and the toxicity associated with systemic therapies. This review discusses the current understanding of TNBC biology, highlighting the urgent need for advanced diagnostics, integrated molecular subtyping, and personalized targeted therapies.

Keywords

triple-negative breast cancer / tumor heterogeneity / immunotherapy / therapeutic challenges

References

[1] Almansour NM. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022; 9: 836417.

[2] Galappaththi SPL, Smith KR, Alsatari ES, Hunter R, Dyess DL, Turbat-Herrera EA, et al. The Genomic and Biologic Landscapes of Breast Cancer and Racial Differences. Int J Mol Sci. 2024; 25: 13165.

[3] Padzińska-Pruszyńska I, Kucharzewska P, Matejuk A, Górczak M, Kubiak M, Taciak B, et al. Macrophages: Key Players in the Battle against Triple-Negative Breast Cancer. Int J Mol Sci. 2024; 25: 10781.

[4] Adrada BE, Moseley TW, Kapoor MM, Scoggins ME, Patel MM, Perez F, et al. Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment. Radiographics. 2023; 43: e230034.

[5] Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023; 381: e071674.

[6] Syeda MF, Santos RA, Sousa LM, Paiva AR, Castelo Branco N, Cunha Pereira T, et al. Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer. Front Immunol. 2025; 16: 1654748.

[7] Brogna MR, Varone V, DelSesto M, Ferrara G. The role of CAFs in therapeutic resistance in triple negative breast cancer: an emerging challenge. Front Mol Biosci. 2025; 12: 1568865.

[8] Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025; 31: 1154-62.

[9] Bhalla K, Xiao Q, Luna JM, Podany E, Ahmad T, Ademuyiwa FO, et al. Radiologic imaging biomarkers in triple-negative breast cancer: a literature review about the role of artificial intelligence and the way forward. BJR Artif Intell. 2024; 1: ubae016.

[10] Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng W, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023; 12: 3.

[11] Mandapati A, Lukong KE. Triple negative breast cancer: approved treatment options and their mechanisms of action. J Cancer Res Clin Oncol. 2023; 149: 3701-19.

[12] van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int J Mol Sci. 2023; 24: 2969.

[13] Agelidis A, Ter-Zakarian A, Jaloudi M. Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond. Breast Cancer (Dove Med Press). 2025; 17: 523-9.

[14] Jie H, Ma W, Huang C. Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review. Breast Cancer (Dove Med Press). 2025; 17: 265-74.

[15] Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, et al. Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. J Clin Med. 2023; 12: 953.

[16] Pai S, Murthy SV. Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center. Indian J Surg Oncol. 2025; 16: 478-90.

[17] Tong L, Yu X, Wang S, Chen L, Wu Y. Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer. Breast Cancer (Dove Med Press). 2023; 15: 647-58.

[18] Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024; 14: 1405491.

[19] Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022; 19: 91-113.

[20] De Santis P, Perrone M, Guarini C, Santoro AN, Laface C, Carrozzo D, et al. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response. Explor Target Antitumor Ther. 2024; 5: 232-50.

[21] Zhou Z, Zhou Q. Immunotherapy resistance in triple-negative breast cancer: Molecular mechanisms, tumor microenvironment, and therapeutic implications. Front Oncol. 2025; 15: 1630464.

[22] Lebedeva V, Ebbinghaus M, Hidalgo JV, Hardt O, Pfeifer R. Triple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects. Int J Mol Sci. 2025; 26: 9714.

[23] Shatalov PA, Bukaeva AA, Veselovsky EM, Traspov AA, Bagdasarova DV, Leukhina IA, et al. Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential. Biomedicines. 2025; 13: 2213.

[24] Kong H, Pan M, Sun L. Identification and analysis of metabolic reprogramming-related genes in triple-negative breast cancer. Clin Exp Med. 2025; 25: 332.

[25] Petrelli F, Tomasello G, Parati MC, Ghidini A, Ghidini M, Borgonovo K, et al. Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials. Medicina (Kaunas). 2024; 60: 341.

[26] Obidiro O, Battogtokh G, Akala EO. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics. 2023; 15: 1796.

[27] Pauls M, Chia S, LeVasseur N. Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer. Curr Oncol. 2022; 29: 4748-67.

[28] Hammershøi Madsen AM, Løvendahl Eefsen RH, Nielsen D, Kümler I. Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review. Breast J. 2024; 2024: 9083055.

[29] Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, et al. Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. Cancers (Basel). 2022; 14: 1253.

[30] Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019; 35: 428-40.

[31] Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021; 31: 178-86.

[32] Liu Y, Zhu XZ, Xiao Y, Wu SY, Zuo WJ, Yu Q, et al. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell Res. 2023; 33: 389-402.

[33] Fan Y, He S. The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. Cancer Manag Res. 2022; 14: 1-17.

[34] Capici S, Ammoni LC, Meli N, Cogliati V, Pepe FF, Piazza F, et al. Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything. Cancers (Basel). 2022; 14: 3729.

[35] Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022; 15: 121.

[36] Fertal SA, Poterala JE, Ponik SM, Wisinski KB. Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer. Cancers (Basel). 2022; 14: 1238.

[37] Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023; 19: 2349-59.

[38] Clark CA, Yang ES. Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer. Front Oncol. 2021; 11: 703802.

[39] Sheng J, Zong X. Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring. Front Oncol. 2025; 15: 1607960.

[40] Lin X, Liu B, Wu J, Shi L, Zhang Y, Yang Q, et al. Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation. Cancer Treat Rev. 2026; 144: 103108.

[41] Cheng C, Wang Y, Zhao J, Wu D, Li H, Zhao H. Deep Learning and Radiomics in Triple-Negative Breast Cancer: Predicting Long-Term Prognosis and Clinical Outcomes. J Multidiscip Healthc. 2025; 18: 319-27.

[42] Choi J, Kim H, Choi Y. Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer. Quant Imaging Med Surg. 2015; 5: 656-64.

[43] Guglielmo P, Triumbari EKA, Cimini A, Camedda R, Urso L, Filippi L. Radionuclide-based nanotechnologies in triple-negative breast cancer: current evidence and future perspectives. Clin Transl Imaging. 2025; 13: 261-74.

[44] Jin G, He R, Liu Q, Dong Y, Lin M, Li W, et al. Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles. ACS Appl Mater Interfaces. 2018; 10: 10634-46.

[45] Pereira R, Coelho JMP, Gaspar MM, Reis CP. Targeting Triple-Negative Breast Cancer: A Special Focus on Phototherapy and Nanomaterials. Molecules. 2026; 31: 511.

[46] Miao L, Kang Y, Zhang XF. Nanotechnology for the theranostic opportunity of breast cancer lung metastasis: recent advancements and future challenges. Front Bioeng Biotechnol. 2024; 12: 1410017.

[47] Nagahashi M, Ling Y, Hayashida T, Kitagawa Y, Futamura M, Yoshida K, et al. Actionable gene alterations in an Asian population with triple-negative breast cancer. JCO Precis Oncol. 2018; 2.

[48] Rodríguez YM, Koomson AA, Perry RJ. Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review. Transl Breast Cancer Res. 2025; 6: 8.

[49] Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer. 2022; 8: 95.

[50] Deng LE, Guo M, Deng Y, Pan Y, Wang X, Maduraiveeran G, et al. MOF-Based Platform for Kidney Diseases: Advances, Challenges, and Prospects. Pharmaceutics. 2024; 16: 793.